Literature DB >> 23804236

Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange.

Angel P Sempere1, Eloísa Feliu-Rey, Rosa Sanchez-Perez, Juan Nieto-Navarro.   

Abstract

Entities:  

Keywords:  MRI; Multiple sclerosis

Mesh：

Substances：

Year:  2013        PMID： 23804236     DOI： 10.1136/jnnp-2013-305456

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Therapeutic management of severe relapses in multiple sclerosis.

Authors:  Carolyn Bevan; Jeffrey M Gelfand
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 2.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

Review 3.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18

4.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

5.  Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.

Authors:  Ayano Shima; Tsuyoshi Hamaguchi; Yasutake Tada; Masahito Yamada
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.